NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-23-047 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-24-151 from the NIH Guide for Grants and Contracts. The goal of CTDPACC is to support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial. The Clinical High Risk for Psychosis Clinical Trial Data Processing, Analysis, and Coordination Center (CTDPACC) will provide executive management, direction, and overall coordination, including data processing and analysis to support the Clinical High Risk (CHR) for Psychosis Clinical Trial Network companion FOA. That Network validates the utility of drug development tools (biomarkers, algorithms, clinical outcome measures) previously assessed in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) project. The CTDPACC will support the efforts of the CHR for Psychosis Clinical Trial Network in a 12-16 week Proof of Principle (PoP) trial utilizing a Phase 2 ready compound or compounds.
Funding Opportunity RFA-MH-24-150 from the NIH Guide for Grants and Contracts. To use a subset of drug development tools, which are being assessed in the AMP SCZ observational study, in a PoP trial with CHR individuals to determine the ability to detect a biological and/or clinical signal with the compound or compounds selected to use within a 12-16 week study period. The PoP trial will assess the performance of the PSYCHS, other clinical outcome measures, and biological measures. The compound or compounds that are selected for testing in the CHR Clinical Trial Network will affect a pathophysiologically relevant mechanism and have the potential to produce a detectable signal on biological and clinical outcome measures within a 12-16 week period of study.
Notice NOT-NS-23-092 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-151 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-23-233 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2023-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Funding Opportunity PA-23-232 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.
Funding Opportunity PA-23-230 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.
Funding Opportunity PA-23-231 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH and CDC awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Funding Opportunity PAR-23-220 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. This Notice of Funding Opportunity requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Funding Opportunity PAR-23-219 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this NOFO.
Notice NOT-MH-23-335 from the NIH Guide for Grants and Contracts
Notice NOT-MH-23-336 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-156 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-157 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-150 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-152 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-216 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to transition the core resources and biomedical research activities of Centers of Biomedical Research Excellence (COBRE) into independence and sustainability.
Funding Opportunity RFA-RM-23-013 from the NIH Guide for Grants and Contracts. The NIH Office of Strategic Coordination (Common Fund - https://commonfund.nih.gov/) has generated many valuable and widely available datasets. The Common Fund Data Ecosystem is helping to ensure that all Common Fund (CF) data are Findable, Accessible, Interoperable, and Reusable (FAIR). The purpose of this Notice of Funding Opportunity (NOFO) is to announce the availability of funds for projects that involve collaboration with multiple CF Data Coordinating Centers (DCCs) to combine discovery and/or translational approaches with work that will enhance reusability of Common Fund data and contribute knowledge to the Common Fund Data Ecosystem. Clinical trials will not be accepted through this NOFO. A clinical trial planning component is allowable, provided it is appropriate and rigorously developed.
Notice NOT-GM-23-048 from the NIH Guide for Grants and Contracts